@nytimes: Wegovy, the popular obesity drug, may have yet another surprising benefit. In a large clinical trial, people taking the drug during the pandemic were 33% less likely to die of Covid-19, researchers reported on Friday. nyti.ms/4cOhZ55

Wegovy, the popular obesity drug, may have yet another surprising benefit. In a large clinical trial, people taking the drug during the pandemic were 33% less likely to die of Covid-19, researchers reported on Friday. https://t.co/6FZ58Bg8pV pic.twitter.com/yG5VjepR7g

— The New York Times (@nytimes) August 30, 2024